MMJ Recs

OCTOBER 2, 2023

California has been a trailblazer in the realm of medical marijuana, offering patients access to a variety of treatment options. If the doctor determines that medical cannabis is a suitable treatment option, they will provide a recommendation for the patient. In 1996, the state became the first in the U.S.

Dispensary 52

Dispensary Patients Environment Conditions 52

Cannabis Law Report

JULY 1, 2021

In 2017, the FDA designated MDMA a breakthrough therapy for post-traumatic stress disorder, and in 2018 the agency recognized psilocybin as a breakthrough therapy for treatment-resistant depression. In contrast, it is unclear to what extent people most in need of psychedelic therapies will benefit.

Law 105

Law Research and Development Therapy DEA 105

Cannabis Law Report

JUNE 27, 2022

So this is going to be more of an issue for y’all who specialize in packaging premium bud for smoking. The FDA and the FTC took joint enforcement action against seven CBD firms for making COVID-19 treatment claims. million in the first month following launch of the program. [link]. But retail is OK! tinyurl.com/2p9hjpa9.

Seed-To-Sale 52

Seed-To-Sale Hemp Retail Treatment 52

Puff Puff Post

NOVEMBER 5, 2019

INM-755 is a single-cannabinoid topical cream under development for the treatment of symptoms associated with epidermolysis bullosa (“EB”). Two strengths of INM-755 cream will be evaluated in 22 adult subjects over a 14-day treatment period. Most types of epidermolysis bullosa are inherited. About INM-755.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Cannabis Law Report

SEPTEMBER 15, 2021

This deceptive marketing of unproven treatments raises significant public health concerns because patients and other consumers may use them instead of approved therapies to treat serious and even fatal diseases. The FDA has received adverse event reports involving delta-8 THC-containing products. brownies, gummies).

THC 105

THC Pets Events Hemp 105

Marijuana Packaging

NOVEMBER 23, 2018

Currently, New England Treatment Access (NETA) in Northampton and Cultivate Holdings in Leicester are the two spots that are selling, with the mayor of Northampton being one of the first customers. Massachusetts Recreational Sales Have Officially Begun. Massachusetts recreational cannabis sales are go. Is New Jersey Next to Legalize?

Legalization 40

Legalization Recreational Therapy Dispensary 40

Cannabis Law Report

AUGUST 10, 2021

Being able to commercially scale our dried flower, while supporting patient care and Canada House’s Veteran program across Canada is something that we are excited to do. As the Canadian medical cannabis market matures, coverage programs will help to ensure long-term sales growth for this segment. providing approx.

Seed-To-Sale 105

Seed-To-Sale Cultivation Patients Cannabis 105

The Joint Blog

OCTOBER 8, 2021

They offer effective treatment for anxiety & stress-related conditions without having any side effects on the body. One study found that people with social phobia felt less anxious in simulated public speaking tests after taking cannabidiol than they did before the treatment, providing evidence for this hypothesis.

Vaping 49

Vaping CBD Blood Pressure Chronic Pain 49

Cannabis Law Report

SEPTEMBER 21, 2021

And regulators need to be thinking in the best interests of consumers who rely on plant-based therapies for their health and quality of life. Are your legislators and the OLCC working on programs to further improve the sector? . No, they need to be re-reviewed. In a perfect world, how would you manage this issue? .

Environment 52

Environment Pharmaceutical Retail Clinical Trials 52

Cannabis Law Report

JULY 30, 2019

In my estimation, the state’s overall program growth in Florida to date is impressive. The ASA highlights that it takes the FDA “an average of 9 years to approve any drug, but it only takes approximately two to four weeks for a medical cannabis patient with chronic pain to be approved by a state program.”

Marijuana 40

Marijuana Education Patients Research and Development 40

Puff Puff Post

NOVEMBER 5, 2019

INM-755 is a single-cannabinoid topical cream under development for the treatment of symptoms associated with epidermolysis bullosa (“EB”). Two strengths of INM-755 cream will be evaluated in 22 adult subjects over a 14-day treatment period. Most types of epidermolysis bullosa are inherited. About INM-755.

Clinical Trials 8

Clinical Trials Pharmaceutical Cannabinoids Data 8

The Cannigma

FEBRUARY 16, 2022

I was like, it’d be cool, if whatever rush you get, that runner’s high, that endorphin, I said, if you could get that and package it, and you could just take that on a regular basis as an athlete, wouldn’t that be amazing? One cohort is specializing in essentially a reentry program. When the term first got talked about.

Trichome 73

Trichome Wellness and Beauty Cannabinoids Cannabis 73